31 August 2017Big Pharma

Video interview: Predicting Brexit’s life sciences impact

The practical implications of Brexit, including on the Unified Patent Court (UPC), were the focus of a roundtable discussion at Life Sciences Patent Network North America, an industry event.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Video interview: Regulatory issues key for life sciences in Brexit debate

25 August 2017 With Brexit negotiations well under way, Nicola Dagg, global head of IP at Allen & Overy, says ensuring that all of the regulatory and compliance requirements are in place immediately after Britain leaves the EU is the most important aspect of negotiations for the life sciences.

Video interview: Novartis discusses challenges around second medical use

23 August 2017 The biggest challenges in the life sciences concern second medical use patents and incentives for innovation, according to Lydia McNally, vice president, head of patents, oncology at Novartis.

More on this story

Video interview: Regulatory issues key for life sciences in Brexit debate

25 August 2017 With Brexit negotiations well under way, Nicola Dagg, global head of IP at Allen & Overy, says ensuring that all of the regulatory and compliance requirements are in place immediately after Britain leaves the EU is the most important aspect of negotiations for the life sciences.

Video interview: Novartis discusses challenges around second medical use

23 August 2017 The biggest challenges in the life sciences concern second medical use patents and incentives for innovation, according to Lydia McNally, vice president, head of patents, oncology at Novartis.

More on this story

Video interview: Regulatory issues key for life sciences in Brexit debate

25 August 2017 With Brexit negotiations well under way, Nicola Dagg, global head of IP at Allen & Overy, says ensuring that all of the regulatory and compliance requirements are in place immediately after Britain leaves the EU is the most important aspect of negotiations for the life sciences.

Video interview: Novartis discusses challenges around second medical use

23 August 2017 The biggest challenges in the life sciences concern second medical use patents and incentives for innovation, according to Lydia McNally, vice president, head of patents, oncology at Novartis.

More features

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic